APPLAUSE-IgAN Clinical Trial
Study at a Glance
Estimated Time Commitment
Eligibility
Age Eligibility: 18 years and olderDiagnosis Required
IgA nephropathy (IgAN)Diseases Being Studied
Currently there are no evidence-based disease-modifying pharmacotherapies for IgAN. The purpose of this clinical trial is to evaluate the superiority of LNP023 (a factor B inhibitor which works by damping the innate immune system) versus placebo on top of the maximally tolerated doses of an ACEi or ARB in slowing kidney disease progression and reduction in the protein in the urine.
Location: Texas Diabetes Institute
Meet Your Clinical Research Team
Contact us
Principal Investigator: Dr. Shweta Bansal; Sponsor: Novartis PharmaceuticalsDr. Shweta Bansal; Sponsor: Novartis Pharmaceuticals